Trending
News

600 Dead in DR Congo Ebola Outbreak

An aggressive Ebola outbreak driven by the rare Bundibugyo strain has claimed 600 lives and infected 1,759 people in the Democratic Republic of Congo, primarily hitting Ituri province. Because no approved vaccines exist for this specific strain, clinical trials for treatments like remdesivir have been fast-tracked.

Daniel Momodu · · 47
600 Dead in DR Congo Ebola Outbreak

The devastating Ebola outbreak in the Democratic Republic of Congo (DRC) has claimed 600 lives, according to recent figures published by the World Health Organization (WHO). This alarming milestone comes just three days after the official death toll surpassed 500, indicating a rapid escalation in fatalities.


Updated data shared by the United Nations health agency reveals that there have been 1,759 confirmed cases of Ebola recorded since the epidemic was officially declared in mid-May 2026. Out of these, 600 have resulted in confirmed deaths, pointing to a severe case fatality rate of approximately 34% in the country. The outbreak, marking the DRC's 17th documented battle with the virus, has affected four provinces but remains intensely concentrated within the conflict-ridden and mineral-rich Ituri province in the northeastern region.


The disease has also crossed borders, with neighboring Uganda reporting 20 confirmed cases, resulting in two deaths and 17 successful patient recoveries so far. In the DRC, 285 individuals have successfully beaten the illness and recovered, while medical teams continue to investigate another 304 suspected cases of the viral hemorrhagic fever.


Unlike prior outbreaks that were contained with public vaccines, this current crisis is being driven by the rare Bundibugyo species of the Ebola virus. Because there are no pre-approved vaccines or standard therapeutic treatments specifically for the Bundibugyo strain, managing the spread has been incredibly challenging. However, response efforts are pivoting toward medical innovation: a clinical trial evaluating two potential treatments, the monoclonal antibody MBP134 and the antiviral drug remdesivir (both individually and in combination), was launched in the DRC on July 2 to help combat the deadly virus.



Share this story

Comments (0)

  1. Be the first to share your thoughts.

Leave a comment

All comments are moderated before publishing. Your email is never published.

Not published.

Related stories